WILKES NSG 533 ADVANCED
PHARMACOLOGY FINAL EXAM
2026/2027: 150 EXAM-STYLE
QUESTIONS WITH ANSWERS AND
DETAILED RATIONALES — PASSAN
SCHOOL OF NURSING MSN PREP
Section 1: Pharmacokinetics & Pharmacodynamics (Q1–
Q25)
Q1. A 70 kg patient receives a 350 mg IV bolus of a drug. The plasma
concentration is measured at 5 mg/L. What is the volume of distribution (Vd)?
A. 7 L
B. 35 L
C. 70 L
D. 350 L
Correct Answer: C. 70 L
Rationale: Vd = Dose / Plasma Concentration. Vd = 350 mg ÷ 5 mg/L = 70 L. The
volume of distribution reflects the extent of drug distribution into body tissues
relative to plasma.
Q2. A patient with cirrhosis and ascites is prescribed a hydrophilic drug. Which
change in drug distribution is most likely?
A. Decreased Vd for water-soluble drugs
B. Increased Vd for hydrophilic drugs
C. Increased protein binding
D. Decreased Vd for lipophilic drugs
Correct Answer: B. Increased Vd for hydrophilic drugs
Rationale: Cirrhosis and ascites increase total body water, expanding the volume
into which hydrophilic drugs distribute. This increases the Vd of water-soluble drugs,
potentially requiring higher loading doses.
Q3. A patient with heart failure has reduced hepatic blood flow. This will most
significantly affect clearance of which drug?
,A. Gentamicin
B. Lidocaine
C. Lithium
D. Digoxin
Correct Answer: B. Lidocaine
Rationale: Lidocaine is a high-extraction-ratio drug, meaning its hepatic clearance is
highly dependent on liver blood flow. Reduced hepatic perfusion in heart failure
significantly decreases lidocaine clearance, increasing toxicity risk.
Q4. A drug follows zero-order kinetics. Which statement is correct?
A. Half-life is constant
B. Doubling the dose doubles the time to eliminate
C. Elimination rate is proportional to concentration
D. Dose-dependent toxicity is a concern
Correct Answer: D. Dose-dependent toxicity is a concern
Rationale: Zero-order kinetics occurs when metabolic enzymes are saturated. A
constant amount of drug is eliminated per unit time regardless of concentration.
Small dose increases can cause disproportionately large increases in plasma
concentration, leading to toxicity. Examples include phenytoin, ethanol, and high-
dose aspirin.
Q5. A patient with hypoalbuminemia is prescribed a highly protein-bound drug.
What is the most likely clinical consequence?
A. Decreased free drug concentration and reduced efficacy
B. Increased free drug concentration and toxicity risk
C. No change in free drug concentration
D. Increased renal excretion of the drug
Correct Answer: B. Increased free drug concentration and toxicity risk
Rationale: Low albumin reduces protein binding sites, increasing the free (active)
fraction of highly protein-bound drugs. This can cause toxicity even at standard
doses. Dose reduction and monitoring are often necessary.
Q6. A 65-year-old patient with decreased renal function is prescribed a
medication that is primarily eliminated by the kidneys. Which pharmacokinetic
parameter is most affected?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Correct Answer: D. Elimination
Rationale: Renal impairment directly affects drug elimination, as the kidneys are the
primary route of excretion for many medications. Decreased GFR leads to drug
accumulation and increased risk of toxicity.
,Q7. A patient is started on a drug with a narrow therapeutic index. Which
statement best describes the clinical significance?
A. The drug has a wide margin of safety
B. Small changes in dose or blood concentration can lead to toxicity or therapeutic
failure
C. The drug requires no monitoring
D. The drug is safe for use in all patient populations
Correct Answer: B. Small changes in dose or blood concentration can lead to
toxicity or therapeutic failure
Rationale: A narrow therapeutic index means there is a small margin between the
minimum effective concentration and the minimum toxic concentration. Drugs with
this characteristic require careful dosing and therapeutic drug monitoring.
Q8. A drug that acts as a competitive antagonist will have which effect on the
dose-response curve of an agonist?
A. Decreased potency with no change in efficacy
B. Decreased efficacy with no change in potency
C. Increased potency with decreased efficacy
D. No change in either potency or efficacy
Correct Answer: A. Decreased potency with no change in efficacy
Rationale: A competitive antagonist binds reversibly to the same receptor site as the
agonist, requiring higher concentrations of agonist to achieve the same effect. This
results in a rightward shift of the dose-response curve (decreased potency) but does
not reduce the maximum possible effect (efficacy).
Q9. Which factor increases the volume of distribution (Vd) of a drug?
A. High plasma protein binding
B. High lipophilicity
C. Low tissue binding
D. Large molecular weight
Correct Answer: B. High lipophilicity
Rationale: High lipophilicity promotes tissue distribution, increasing the volume of
distribution. High plasma protein binding decreases Vd by keeping the drug in the
vascular compartment.
Q10. Which pharmacokinetic process is primarily affected by a patient's serum
albumin levels?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: B. Distribution
Rationale: Distribution involves the transport of a drug by the bloodstream to its site
, of action. Serum albumin levels affect protein binding, which influences the free
fraction of drug available for distribution.
Q11. A patient is receiving a drug that undergoes significant first-pass
metabolism. Which route of administration would most effectively bypass this
effect?
A. Oral
B. Sublingual
C. Rectal
D. Intravenous
Correct Answer: D. Intravenous
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract pass
through the liver before reaching systemic circulation. Intravenous administration
completely bypasses this effect by delivering the drug directly into systemic
circulation.
Q12. Drug clearance is best defined as:
A. The volume of blood from which the drug is completely removed per unit time
B. The time required for the drug concentration to decrease by half
C. The amount of drug absorbed after oral administration
D. The volume in which the drug is distributed
Correct Answer: A. The volume of blood from which the drug is completely
removed per unit time
Rationale: Clearance describes the efficiency of drug removal from the body,
expressed as volume cleared per unit time (e.g., mL/min).
Q13. A patient with renal impairment is prescribed digoxin. Which
pharmacokinetic parameter is most directly affected, increasing the risk of
toxicity?
A. Volume of distribution
B. Protein binding
C. Renal clearance
D. Hepatic metabolism
Correct Answer: C. Renal clearance
Rationale: Digoxin is excreted predominantly unchanged by the kidneys. Reduced
renal clearance leads to accumulation and increased risk of toxicity.
Q14. What determines a drug's volume of distribution?
A. The dose administered and plasma concentration
B. The rate of absorption from the GI tract
C. The extent of protein binding
D. The rate of hepatic metabolism
Correct Answer: A. The dose administered and plasma concentration
Rationale: Vd is calculated as the amount of drug in the body divided by the plasma
PHARMACOLOGY FINAL EXAM
2026/2027: 150 EXAM-STYLE
QUESTIONS WITH ANSWERS AND
DETAILED RATIONALES — PASSAN
SCHOOL OF NURSING MSN PREP
Section 1: Pharmacokinetics & Pharmacodynamics (Q1–
Q25)
Q1. A 70 kg patient receives a 350 mg IV bolus of a drug. The plasma
concentration is measured at 5 mg/L. What is the volume of distribution (Vd)?
A. 7 L
B. 35 L
C. 70 L
D. 350 L
Correct Answer: C. 70 L
Rationale: Vd = Dose / Plasma Concentration. Vd = 350 mg ÷ 5 mg/L = 70 L. The
volume of distribution reflects the extent of drug distribution into body tissues
relative to plasma.
Q2. A patient with cirrhosis and ascites is prescribed a hydrophilic drug. Which
change in drug distribution is most likely?
A. Decreased Vd for water-soluble drugs
B. Increased Vd for hydrophilic drugs
C. Increased protein binding
D. Decreased Vd for lipophilic drugs
Correct Answer: B. Increased Vd for hydrophilic drugs
Rationale: Cirrhosis and ascites increase total body water, expanding the volume
into which hydrophilic drugs distribute. This increases the Vd of water-soluble drugs,
potentially requiring higher loading doses.
Q3. A patient with heart failure has reduced hepatic blood flow. This will most
significantly affect clearance of which drug?
,A. Gentamicin
B. Lidocaine
C. Lithium
D. Digoxin
Correct Answer: B. Lidocaine
Rationale: Lidocaine is a high-extraction-ratio drug, meaning its hepatic clearance is
highly dependent on liver blood flow. Reduced hepatic perfusion in heart failure
significantly decreases lidocaine clearance, increasing toxicity risk.
Q4. A drug follows zero-order kinetics. Which statement is correct?
A. Half-life is constant
B. Doubling the dose doubles the time to eliminate
C. Elimination rate is proportional to concentration
D. Dose-dependent toxicity is a concern
Correct Answer: D. Dose-dependent toxicity is a concern
Rationale: Zero-order kinetics occurs when metabolic enzymes are saturated. A
constant amount of drug is eliminated per unit time regardless of concentration.
Small dose increases can cause disproportionately large increases in plasma
concentration, leading to toxicity. Examples include phenytoin, ethanol, and high-
dose aspirin.
Q5. A patient with hypoalbuminemia is prescribed a highly protein-bound drug.
What is the most likely clinical consequence?
A. Decreased free drug concentration and reduced efficacy
B. Increased free drug concentration and toxicity risk
C. No change in free drug concentration
D. Increased renal excretion of the drug
Correct Answer: B. Increased free drug concentration and toxicity risk
Rationale: Low albumin reduces protein binding sites, increasing the free (active)
fraction of highly protein-bound drugs. This can cause toxicity even at standard
doses. Dose reduction and monitoring are often necessary.
Q6. A 65-year-old patient with decreased renal function is prescribed a
medication that is primarily eliminated by the kidneys. Which pharmacokinetic
parameter is most affected?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Correct Answer: D. Elimination
Rationale: Renal impairment directly affects drug elimination, as the kidneys are the
primary route of excretion for many medications. Decreased GFR leads to drug
accumulation and increased risk of toxicity.
,Q7. A patient is started on a drug with a narrow therapeutic index. Which
statement best describes the clinical significance?
A. The drug has a wide margin of safety
B. Small changes in dose or blood concentration can lead to toxicity or therapeutic
failure
C. The drug requires no monitoring
D. The drug is safe for use in all patient populations
Correct Answer: B. Small changes in dose or blood concentration can lead to
toxicity or therapeutic failure
Rationale: A narrow therapeutic index means there is a small margin between the
minimum effective concentration and the minimum toxic concentration. Drugs with
this characteristic require careful dosing and therapeutic drug monitoring.
Q8. A drug that acts as a competitive antagonist will have which effect on the
dose-response curve of an agonist?
A. Decreased potency with no change in efficacy
B. Decreased efficacy with no change in potency
C. Increased potency with decreased efficacy
D. No change in either potency or efficacy
Correct Answer: A. Decreased potency with no change in efficacy
Rationale: A competitive antagonist binds reversibly to the same receptor site as the
agonist, requiring higher concentrations of agonist to achieve the same effect. This
results in a rightward shift of the dose-response curve (decreased potency) but does
not reduce the maximum possible effect (efficacy).
Q9. Which factor increases the volume of distribution (Vd) of a drug?
A. High plasma protein binding
B. High lipophilicity
C. Low tissue binding
D. Large molecular weight
Correct Answer: B. High lipophilicity
Rationale: High lipophilicity promotes tissue distribution, increasing the volume of
distribution. High plasma protein binding decreases Vd by keeping the drug in the
vascular compartment.
Q10. Which pharmacokinetic process is primarily affected by a patient's serum
albumin levels?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: B. Distribution
Rationale: Distribution involves the transport of a drug by the bloodstream to its site
, of action. Serum albumin levels affect protein binding, which influences the free
fraction of drug available for distribution.
Q11. A patient is receiving a drug that undergoes significant first-pass
metabolism. Which route of administration would most effectively bypass this
effect?
A. Oral
B. Sublingual
C. Rectal
D. Intravenous
Correct Answer: D. Intravenous
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract pass
through the liver before reaching systemic circulation. Intravenous administration
completely bypasses this effect by delivering the drug directly into systemic
circulation.
Q12. Drug clearance is best defined as:
A. The volume of blood from which the drug is completely removed per unit time
B. The time required for the drug concentration to decrease by half
C. The amount of drug absorbed after oral administration
D. The volume in which the drug is distributed
Correct Answer: A. The volume of blood from which the drug is completely
removed per unit time
Rationale: Clearance describes the efficiency of drug removal from the body,
expressed as volume cleared per unit time (e.g., mL/min).
Q13. A patient with renal impairment is prescribed digoxin. Which
pharmacokinetic parameter is most directly affected, increasing the risk of
toxicity?
A. Volume of distribution
B. Protein binding
C. Renal clearance
D. Hepatic metabolism
Correct Answer: C. Renal clearance
Rationale: Digoxin is excreted predominantly unchanged by the kidneys. Reduced
renal clearance leads to accumulation and increased risk of toxicity.
Q14. What determines a drug's volume of distribution?
A. The dose administered and plasma concentration
B. The rate of absorption from the GI tract
C. The extent of protein binding
D. The rate of hepatic metabolism
Correct Answer: A. The dose administered and plasma concentration
Rationale: Vd is calculated as the amount of drug in the body divided by the plasma
